[1]
|
S. H. Daukes, “A Consideration of the Various Methods of Drug Administration,” Post Graduate Medical Journal, Vol. 5, No. 49, 1929, pp. 1-7. doi:10.1136/pgmj.5.49.1
|
[2]
|
J. Smieja, et al., “Optimal Control for the Model of Drug Resistance Resulting from Gen Amplification,” Preperation of the 14th IFAC World Congress, Beijing, China, Vol. 50, 1999, pp. 71-75.
|
[3]
|
A. Swierniak et al., “Asymptotic Properties of Infinite Dimensional Model Drug Resistance Evolution,” Proceedings of the European Control Conference (ECC), Brussels, 1997.
|
[4]
|
W. E. Evans and H. L. McLeod, “Pharmacogenomics— drug disposition, drug targets, and side effects,” New England Journal of Medicine, Vol. 348, No. 6, 2003, pp. 538-549. doi:10.1056/NEJMra020526
|
[5]
|
C. Abad-Zapatero and J. T. Metz, “Ligand Efficiency In- dices as Guideposts for Drug Discovery,” Drug Discovery Today, Vol. 10, No. 7, 2005, pp. 464-469.
doi:10.1016/S1359-6446(05)03386-6
|
[6]
|
C. Hetenyi, et al., “Structure-Based Calculation of Drug Efficiency Indices,” Journal of Structural Bioinformatics, Vol. 23, No. 20, 2007, pp. 2678-2685.
doi:10.1093/bioinformatics/btm431
|
[7]
|
P. Tirupathi Rao and R. Bharathi, “Stochastic Modeling in the Evaluation of Drug Efficiency,” International Journal of Statistics and System, Vol. 5, No. 3, 2010, pp. 427-438.
|